Some data have confirmed that the expression of JAK2 is abnormally increased in approximately 30% of Hodgkin’s lymphoma (HL) and 30–50% of primary mediastinal large B-cell lymphoma (PMBCL), suggesting that the abnormal activation of JAK2 is associated with the development of lymphoma [17, 18]. Here, JAK2 is linked to lymphoma.